Clinical Trials Logo

Clinical Trial Summary

Phase I study designed to characterize the pharmacokinetics (PK), safety, and tolerability of a single subcutaneous (s.c.) injection of pelacarsen in participants with mild hepatic impairment (HI) compared to matched healthy participants. This study will assess whether mild HI may affect the PK of pelacarsen.


Clinical Trial Description

This is a Phase I study designed to characterize the pharmacokinetics (PK), safety, and tolerability of a single subcutaneous (s.c.) injection of pelacarsen in participants with mild hepatic impairment (HI) compared to matched healthy participants. This study will assess whether mild HI may affect the PK of pelacarsen. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05026996
Study type Interventional
Source Novartis
Contact Novartis Pharmaceuticals
Phone 1-888-669-6682
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date September 13, 2021
Completion date March 29, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04552808 - To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy Subjects Phase 1
Completed NCT04546789 - Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK Phase 1
Completed NCT04473664 - A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment Phase 1
Not yet recruiting NCT04993157 - Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment Phase 1
Completed NCT03282513 - A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function Phase 1
Completed NCT03290443 - A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment. Phase 1
Not yet recruiting NCT05045482 - Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease Phase 1
Completed NCT02244827 - Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment Phase 1
Completed NCT02245243 - Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment Phase 1
Completed NCT02004587 - Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers Phase 1
Completed NCT01621633 - A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers Phase 2
Completed NCT01493869 - Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects Phase 1
Completed NCT04482270 - A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function Phase 1
Completed NCT02115347 - Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014) Phase 1
Withdrawn NCT03277755 - A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function Phase 1
Not yet recruiting NCT04759846 - Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma Phase 1
Completed NCT04091061 - Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects Phase 1
Recruiting NCT04643795 - Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects Phase 1
Active, not recruiting NCT04020016 - Nalbuphine ER Effects of Liver Disease on Pharmacokinetics and Itch Phase 1